// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

EFFECTS OF DAPAGLIFLOZIN AND DAPAGLIFLOZIN PLUS SAXAGLIPTIN ON HbA1c AND ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: PHASE II/III DELIGHT STUDY

C. Pollock - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Dapagliflozin

RITUXIMAB IN FREQUENTLY-RELAPSING/ STEROID-DEPENDENT NEPHROTIC SYNDROME: WHAT IS THE OPTIMAL REGIMEN?

E.Y.H. Chan - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Nephrotic syndrome

Rituximab

ACEi/ARBs, β-blockers or Both in incident End-Stage Renal Disease patients without Cardiovascular Disease: A Propensity-Matched longitudinal study in a Nationwide cohort

J.P. Ferreira - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

N/A

SURVIVAL OF SOUTH AFRICAN PATIENTS ON RENAL REPLACEMENT THERAPY

M.R. Davids - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

DATA ITEM COLLECTION BY RENAL REGISTRIES AROUND THE WORLD – RESULTS FROM THE SharE-RR SURVEY

K. EVANS - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

ESTABLISHING REGISTRIES FOR KIDNEY HEALTH ADVOCACY – RESULTS FROM THE SharE-RR SURVEY

B. HOLE - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

HAEMODIAFILTRATION IMPROVES THE CARDIOVASCULAR RISK PROFILE AND PATIENT RELATED OUTCOME MEASURES COMPARED TO CONVENTIONAL HAEMODIALYSIS IN CHILDREN – THE HDF, HEART AND HEIGHT (3H STUDY

R. Shroff - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A META-ANALYSIS OF THE REPRESENTATIVENESS OF RANDOMIZED CONTROLLED TRIAL COHORTS IN END-STAGE KIDNEY DISEASE

B. Smyth - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

N/A

VALIDATING CONTINUOUS GLUCOSE MONITORING SYSTEM IN HAEMODIALYSIS PATIENTS

T. KASHEM - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

OUTCOMES OF ONCE DAILY IMMUNOSUPPRESSION IN YOUNG ADULTS WITH RENAL TRANSPLANTS

T. KWAN - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Oraprine

“A SWORD OF DAMOCLES”: PATIENT AND CAREGIVER BELIEFS, ATTITUDES AND PERSPECTIVES ON GENETIC SCREENING AND TESTING FOR AUTOSOMAL POLYCYSTIC KIDNEY DISEASE - FOCUS GROUP STUDY

C. LOGEMAN - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Polycystic kidney disease

Prulifloxacin

GROUP 2 INNATE LYMPHOID CELLS ARE REDUNDANT IN EXPERIMENTAL RENAL ISCHEMIA-REPERFUSION INJURY

G. CAMERON - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal ischemia reperfusion injury

Interleukin

THE SAVING YOUNG LIVES PROGRAM: PROOF OF PRINCIPLE AND OVERCOMING BARRIERS

B. Cullis - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

THE PERFORMANCE OF A POINT-OF-CARE SALIVARY UREA NITROGEN DIPSTICK TO DETECT KIDNEY DISEASE IN DISTRICT AND COMMUNITY SETTINGS IN MALAWI

R. Evans - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

THE INCIDENCE AND SEVERITY OF COMMUNITY-ACQUIRED ACUTE KIDNEY INJURY AMONGST UNSELECTED MEDICAL ADMISSIONS IN A RURAL DISTRICT HOSPITAL IN SIERRA LEONE

A. Beck - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Acute renal failure

N/A

IMPACT OF BODY MASS INDEX ON RENAL AND MORTALITY OUTCOMES AFTER ACUTE KIDNEY INJURY: A SYSTEMATIC REVIEW

R. Blacklock - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

End stage renal disease

N/A

HOW TO ESTIMATE GLOMERULAR FILTRATION RATE IN SUB-SAHARAN AFRICA: DESIGN AND METHODS OF THE AFRICAN RESEARCH ON KIDNEY DISEASES (ARK STUDY

R. Kalyesubula - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal disease

Omnipaque 350

CARDIO-RENAL-METABOLIC COMORBIDITIES AND ASSOCIATION WITH CARDIOVASCULAR OUTCOMES AND MORTALITY IN NEWLY DIAGNOSED PATIENTS WITH T2DM

D. Cherney - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

USE OF DIGITAL MEDIA AS AN ADJUVANT TOOL IN THE PREVENTION AND TREATMENT OF CHRONIC KIDNEY DISEASE

G. Da Silva Jr. - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

HEALTH LITERACY ON KIDNEY DISEASE IN A REGION OF PORTUGAL: RESULTS OF A CROSS-SECTIONAL STUDY

G. Da Silva Jr. - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal disease

N/A

Copyright © 2026. QuantiNova All rights reserved